Rock Creek Group, LP Cognition Therapeutics Inc Transaction History

Rock Creek Group, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$1.56 - $3.38 $62,053 - $134,449	-39,778 Reduced 79.56%	10,222 $18,000
Q3 2022 Nov 10, 2022	SELL	$1.63 - $3.6 $48,494 - $107,103	-29,751 Reduced 37.3%	50,000 $95,000
Q2 2022 Aug 08, 2022	BUY	$1.5 - $3.45 $79,968 - $183,926	53,312 Added 201.64%	79,751 $170,000
Q4 2021 Feb 11, 2022	BUY	$5.1 - $12.98 $134,838 - $343,178	26,439 New	26,439 $167,000

7.62M

Ticker CGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,710,700
Market Cap $9.99M
Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...

Get notified when there are updates to the investment portfolio of Rock Creek Group, LP, based on Form 13F filings with the SEC.

Stay updated on Rock Creek Group, LP with notifications on news.